Контрацептивные и лечебные эффекты комбинированного орального контрацептива с дроспиреноном

The article presents data on the clinical and contraceptive capabilities of an estrogen-progestogen drug containing drospirenone (Midiana). By its pharmacological properties, drospirenone is close to endogenous progesterone and has gestagenic, antiandrogenic and antimineralocorticoid action. With a high affinity for progesterone receptors, drospirenone suppresses ovulation, reliably protects against unwanted pregnancy and provides an additional contraceptive effect. Combined oral contraceptives with drospirenone, taking into account their antiandrogenic and antimineralocorticoid properties, are successfully used in the treatment of premenstrual syndrome, polycystic ovaries, hyperandrogenism and in the prevention of endometrial hyperplastic processes without causing significant weight change.